EzzatiMLopezADRodgersAet al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet2002; 360: 1347–1360.
2.
LawMRMorrisJKWaldNJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ2009; 338: b1665–b1665.
3.
PiepoliMFHoesAWAgewallSet al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol2016; 23: NP1–NP96.
4.
The Lancet Editors. Retraction—Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet2013; 382: 843–843.
5.
BikdeliBPunnanithinontNAkramYet al.Two decades of cardiovascular trials with primary surrogate endpoints: 1990–2011. J Am Heart Assoc2017; 6: e005285–e005285.
6.
The CAFE Investigators, CAFE Steering Committee and Writing Committee, Bryan Williams, et al.; for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Circulation 2006; 113: 1213–1225.
Van VarkLCBertrandMAkkerhuisKMet al.Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158,998 patients. Eur Heart J2012; 33: 2088–2097.
9.
BakerWLColemanCIKlugerJet al.Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med2009; 151: 861–871.
10.
HaoGWangZGuoRet al.Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled studies. BMC Cardiovasc Disord2014; 14: 148–148.
11.
YusufSTeoKKPogueJet al.Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med2008; 358: 1547–1559.
12.
BarnettAHBainSCBouterPet al.Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N Engl J Med2014; 351: 1952–1961.
13.
CeconiCFrancoliniGOlivaresAet al.Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol2007; 577: 1–6.
